454 Life Sciences' Early Access Customers Present Promising First Sequencing Application Data with the New GS Junior System

BRANFORD, Conn.--(BUSINESS WIRE)--At the analytica conference today in Munich, Germany, a group of early access users shared their first results using the GS Junior System, a new bench top high-throughput sequencing platform for life science research use from 454 Life Sciences, a Roche Company (SWX:RO)(SWX:ROG)(Pink Sheets:RHHBY). The presentations, which ranged from studies on targeted amplicon sequencing to whole genome sequencing of bacterial genomes, underscore the speed at which the researchers were able to progress from hypothesis to biologically relevant results.

Back to news